cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.29235917
title: Supplementary Material for: Biofeedback and Training of Interoceptive Insight and Metacognitive Efficacy Beliefs (InMe) to Improve Adaptive Interoception: A Subclinical Randomised Controlled Trial

description: Introduction
Interoception, the sensing, awareness and regulation of physiological states, is crucial for wellbeing and mental health. Behavioural interventions targeting interoception exist, but Randomised Control Trials (RCTs) testing efficacy remain limited. The present, preregistered (ISRCTN16762367) RCT tested the novel Interoceptive iNsight and Metacognitive Efficacy beliefs (InMe) intervention. InMe uses slow-breathing and cardiac biofeedback during stress to train interoceptive self-efficacy beliefs and improve self-reported interoception.
Methods
Healthy participants aged 18-30 years with low self-reported interoception were randomly assigned (1:1) to the InMe intervention (n=50) or an active control (guided imagery; n=52). Participants blinded to allocation were stratified by gender and disordered eating. Assessments included baseline (T0), post-intervention (T1), and 7-8 weeks post-intervention (T2). The primary outcome was the “Adaptive Interoception” factor of the Multidimensional Assessment of Interoceptive Awareness questionnaire. 
Results
Both arms improved in the primary outcome at T1 (InMe:adjusted M difference=5.76; 95%CI[-0.03;11.56], p=0.05; Control:adjusted M difference=7.90; 95%CI[1.92;13.87], p=0.002; Marginal R2=0.09). However, only InMe sustained this improvement at T2 (InMe:adjusted M difference=9.25, 95%CI[3.37;15.13], p&lt;0.001; Control:adjusted M difference=2.94, 95%CI[-3.07; 8.96], p=0.72), as indicated by a significant Time*Arm interaction (b=6.31; SE=2.92, 95%CI[0.56;12.05], p&lt;0.03; Marginal R2=0.12). Secondary outcomes showed a reduction in disordered eating scores across both arms at both time points (T1:b=-1.44, SE=0.37, 95%CI[-2.17;-0.71], p&lt;0.001; T2: b=-1.05, SE=0.37, 95%CI[-1.79; -0.32], p=0.005). 
Conclusion
The InMe intervention selectively improved self-reported interoception at follow-up but did not outperform the Control for secondary outcomes. Future research should explore its efficacy in clinical populations alongside complementary therapies.
DOI: 10.6084/m9.figshare.29235917.v1
title: Supplementary Material for: Biofeedback and Training of Interoceptive Insight and Metacognitive Efficacy Beliefs (InMe) to Improve Adaptive Interoception: A Subclinical Randomised Controlled Trial

description: Introduction
Interoception, the sensing, awareness and regulation of physiological states, is crucial for wellbeing and mental health. Behavioural interventions targeting interoception exist, but Randomised Control Trials (RCTs) testing efficacy remain limited. The present, preregistered (ISRCTN16762367) RCT tested the novel Interoceptive iNsight and Metacognitive Efficacy beliefs (InMe) intervention. InMe uses slow-breathing and cardiac biofeedback during stress to train interoceptive self-efficacy beliefs and improve self-reported interoception.
Methods
Healthy participants aged 18-30 years with low self-reported interoception were randomly assigned (1:1) to the InMe intervention (n=50) or an active control (guided imagery; n=52). Participants blinded to allocation were stratified by gender and disordered eating. Assessments included baseline (T0), post-intervention (T1), and 7-8 weeks post-intervention (T2). The primary outcome was the “Adaptive Interoception” factor of the Multidimensional Assessment of Interoceptive Awareness questionnaire. 
Results
Both arms improved in the primary outcome at T1 (InMe:adjusted M difference=5.76; 95%CI[-0.03;11.56], p=0.05; Control:adjusted M difference=7.90; 95%CI[1.92;13.87], p=0.002; Marginal R2=0.09). However, only InMe sustained this improvement at T2 (InMe:adjusted M difference=9.25, 95%CI[3.37;15.13], p&lt;0.001; Control:adjusted M difference=2.94, 95%CI[-3.07; 8.96], p=0.72), as indicated by a significant Time*Arm interaction (b=6.31; SE=2.92, 95%CI[0.56;12.05], p&lt;0.03; Marginal R2=0.12). Secondary outcomes showed a reduction in disordered eating scores across both arms at both time points (T1:b=-1.44, SE=0.37, 95%CI[-2.17;-0.71], p&lt;0.001; T2: b=-1.05, SE=0.37, 95%CI[-1.79; -0.32], p=0.005). 
Conclusion
The InMe intervention selectively improved self-reported interoception at follow-up but did not outperform the Control for secondary outcomes. Future research should explore its efficacy in clinical populations alongside complementary therapies.
DOI: 10.6084/m9.figshare.29235920
title: Supplementary Material for: Long term survival in pancreatic adenocarcinoma with metachronous hepatic metastases using multimodality treatment including pegylated liposomal irinotecan and capecitabine: a case report

description: Introduction
Pegylated liposomal irinotecan (nal-IRI) in combination with fluorouracil (5-FU) and leucovorin (LV) has achieved a median overall survival of 6.1 months in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) who progressed on gemcitabine-based chemotherapy. The case of a patient with considerable long-term survival on second-line nal-IRI-based therapy is presented.
Case presentation
A 70-year-old male presented with weight loss and abdominal pain in July 2018, was diagnosed with stage IB PDAC (pT2, pN0, M0), and underwent successful R0 resection. Adjuvant chemotherapy with FOLFIRINOX (5-FU, LV, irinotecan, and oxaliplatin) was given for nine cycles between September 2018 and January 2019, and the patient remained recurrence-free until a computed tomography scan revealed soft tissue mesenteric infiltrations in July 2020. First-line palliative chemotherapy with nab-paclitaxel + gemcitabine was initiated and continued until January 2022 when disease progression in the form of two metastatic hepatic lesions was observed. Second-line palliative chemotherapy with nal-IRI 129 mg on day 1 + capecitabine (CAP) 4000 mg daily for the first 7 days of each 14-day cycle was initiated (due to previous 5-FU intolerance). Response (reduced oncomarkers) was observed, and treatment with nal-IRI + CAP continued, with liver-directed treatment in September 2023, until February 2024. During second-line therapy, side effects (mild diarrhoea) were infrequent and manageable.
Conclusion 
This patient achieved an extraordinary survival of 25 months with second-line treatment with nal-IRI + CAP. Nal-IRI-based therapy has the potential to provide long-term survival in the presence of favourable prognostic factors such as moderately elevated CA 19-9 levels.
DOI: 10.6084/m9.figshare.29235920.v1
title: Supplementary Material for: Long term survival in pancreatic adenocarcinoma with metachronous hepatic metastases using multimodality treatment including pegylated liposomal irinotecan and capecitabine: a case report

description: Introduction
Pegylated liposomal irinotecan (nal-IRI) in combination with fluorouracil (5-FU) and leucovorin (LV) has achieved a median overall survival of 6.1 months in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) who progressed on gemcitabine-based chemotherapy. The case of a patient with considerable long-term survival on second-line nal-IRI-based therapy is presented.
Case presentation
A 70-year-old male presented with weight loss and abdominal pain in July 2018, was diagnosed with stage IB PDAC (pT2, pN0, M0), and underwent successful R0 resection. Adjuvant chemotherapy with FOLFIRINOX (5-FU, LV, irinotecan, and oxaliplatin) was given for nine cycles between September 2018 and January 2019, and the patient remained recurrence-free until a computed tomography scan revealed soft tissue mesenteric infiltrations in July 2020. First-line palliative chemotherapy with nab-paclitaxel + gemcitabine was initiated and continued until January 2022 when disease progression in the form of two metastatic hepatic lesions was observed. Second-line palliative chemotherapy with nal-IRI 129 mg on day 1 + capecitabine (CAP) 4000 mg daily for the first 7 days of each 14-day cycle was initiated (due to previous 5-FU intolerance). Response (reduced oncomarkers) was observed, and treatment with nal-IRI + CAP continued, with liver-directed treatment in September 2023, until February 2024. During second-line therapy, side effects (mild diarrhoea) were infrequent and manageable.
Conclusion 
This patient achieved an extraordinary survival of 25 months with second-line treatment with nal-IRI + CAP. Nal-IRI-based therapy has the potential to provide long-term survival in the presence of favourable prognostic factors such as moderately elevated CA 19-9 levels.
DOI: 10.6084/m9.figshare.29235923
title: Supplementary Material for: Subclavian artery-internal carotid artery bypass using a radial-artery graft for common carotid artery occlusion with immediate improvement of cognitive function: A case report

description: Introduction: Although rare, common carotid artery occlusion (CCAO) causes ischemic neurological dysfunction, which can be treated by revascularization. Although several bypass approaches for CCAO have been suggested, no consensus on the surgical revascularization approach and its functional outcome have been reached. Herein, we present a case of Riles type 1A CCAO in which a subclavian artery–internal carotid artery bypass using a radial artery graft resulted in immediate recovery of cognitive function and successfully prevented ischemic stroke.
Case Description: A 58-year-old man presented with recurrent episodes of right-sided weakness. Brain magnetic resonance imaging revealed multiple cerebral infarcts. Digital subtraction angiography confirmed left CCAO and no anterograde blood flow in the left internal carotid artery (ICA) and ipsilateral external carotid artery. A bypass was performed from the left subclavian artery (SclA) to the left cervical ICA using a left radial artery graft (RAG), and supraclavicular anastomosis between the SclA and ICA was performed without graft-vessel kinking. Postoperatively, no neurological deficits were observed, and his cognitive function was successfully improved.
Conclusion: SclA–ICA bypass using an RAG can be a reasonable treatment option for CCAO. CCAO revascularization can prevent ischemic stroke and improve cognitive function.
DOI: 10.6084/m9.figshare.29235923.v1
title: Supplementary Material for: Subclavian artery-internal carotid artery bypass using a radial-artery graft for common carotid artery occlusion with immediate improvement of cognitive function: A case report

description: Introduction: Although rare, common carotid artery occlusion (CCAO) causes ischemic neurological dysfunction, which can be treated by revascularization. Although several bypass approaches for CCAO have been suggested, no consensus on the surgical revascularization approach and its functional outcome have been reached. Herein, we present a case of Riles type 1A CCAO in which a subclavian artery–internal carotid artery bypass using a radial artery graft resulted in immediate recovery of cognitive function and successfully prevented ischemic stroke.
Case Description: A 58-year-old man presented with recurrent episodes of right-sided weakness. Brain magnetic resonance imaging revealed multiple cerebral infarcts. Digital subtraction angiography confirmed left CCAO and no anterograde blood flow in the left internal carotid artery (ICA) and ipsilateral external carotid artery. A bypass was performed from the left subclavian artery (SclA) to the left cervical ICA using a left radial artery graft (RAG), and supraclavicular anastomosis between the SclA and ICA was performed without graft-vessel kinking. Postoperatively, no neurological deficits were observed, and his cognitive function was successfully improved.
Conclusion: SclA–ICA bypass using an RAG can be a reasonable treatment option for CCAO. CCAO revascularization can prevent ischemic stroke and improve cognitive function.
DOI: 10.6084/m9.figshare.29235926
title: Supplementary Material for: Evaluation of safety of elacestrant in patients with breast cancer: Insights from FDA adverse event reporting system database analysis

description: Introduction: This study aims to evaluate the safety profile of elacestrant in real-world settings using data from the FDA adverse event reporting system (FAERS) database, offering insights to inform clinical use.
Methods: Data are collected from the FAERS database spanning the first quarter of 2023 through the third quarter of 2024. Adverse events (AEs) associated with elacestrant are identified using reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and multinomial gamma Poisson shrinkage (MGPS) analyses. The temporal distribution of AEs is assessed using Weibull distribution to evaluate the drug's safety comprehensively.
Results: Reports of 6,476 AEs with elacestrant as the primary suspect (PS) drug are identified, spanning 27 organ systems. A total of 53 preferred terms (PTs) signal are detected across four algorithms, including known adverse reactions such as nausea, vomiting, fatigue, elevated blood cholesterol, and musculoskeletal pain. Potential new AEs, including pathological fractures, gastroesophageal reflux disease, hypokalemia, lymphoedema, and dehydration are also identified. The median onset time for elacestrant-related AEs is 44 days, with most events occurring within the first month of treatment.
Conclusion: This study offers real-world insights into elacestrant usage, confirming known adverse reactions and identifying previously unreported events. These findings provide valuable guidance for clinicians in minimizing drug risks during treatment.
DOI: 10.6084/m9.figshare.29235926.v1
title: Supplementary Material for: Evaluation of safety of elacestrant in patients with breast cancer: Insights from FDA adverse event reporting system database analysis

description: Introduction: This study aims to evaluate the safety profile of elacestrant in real-world settings using data from the FDA adverse event reporting system (FAERS) database, offering insights to inform clinical use.
Methods: Data are collected from the FAERS database spanning the first quarter of 2023 through the third quarter of 2024. Adverse events (AEs) associated with elacestrant are identified using reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and multinomial gamma Poisson shrinkage (MGPS) analyses. The temporal distribution of AEs is assessed using Weibull distribution to evaluate the drug's safety comprehensively.
Results: Reports of 6,476 AEs with elacestrant as the primary suspect (PS) drug are identified, spanning 27 organ systems. A total of 53 preferred terms (PTs) signal are detected across four algorithms, including known adverse reactions such as nausea, vomiting, fatigue, elevated blood cholesterol, and musculoskeletal pain. Potential new AEs, including pathological fractures, gastroesophageal reflux disease, hypokalemia, lymphoedema, and dehydration are also identified. The median onset time for elacestrant-related AEs is 44 days, with most events occurring within the first month of treatment.
Conclusion: This study offers real-world insights into elacestrant usage, confirming known adverse reactions and identifying previously unreported events. These findings provide valuable guidance for clinicians in minimizing drug risks during treatment.
DOI: 10.6084/m9.figshare.29235929
title: Supplementary Material for: Remarkable Response to Cisplatin-Based Chemotherapy and Long-Term Remission in a Young Male with Widespread Extragonadal Choriocarcinoma: A Case Report and Literature Review

description: Introduction
Choriocarcinoma is a rare and aggressive germ cell tumor (GCT) that presents significant diagnostic challenges, particularly in males, where it is typically found in the gonads. Most patients present with advanced disease, often exhibiting symptoms related to metastatic spread, such as shortness of breath, cough, and hemoptysis. The rarity of extragonadal choriocarcinoma and its non-specific presentation make early diagnosis difficult, emphasizing the need for a multidisciplinary approach to treatment.
Case Presentation
A 31-year-old male presented with progressive shortness of breath, cough, and hemoptysis over a month. Initial imaging revealed multiple pulmonary nodules and a large necrotic retroperitoneal mass, along with liver metastases. The patient’s β-human chorionic gonadotropin (β-hCG) levels were markedly elevated, raising suspicion of choriocarcinoma, which was subsequently confirmed through biopsy. Given the rapid clinical deterioration, chemotherapy with Cisplatin and Etoposide was initiated. The patient responded well to treatment, with a significant reduction in tumor and metastasis size. Over 30 months of follow-up, the patient showed continued clinical improvement with no evidence of disease recurrence.
Conclusion
Extragonadal choriocarcinoma is a highly aggressive and rare malignancy that poses significant diagnostic and therapeutic challenges. This case underscores the importance of early intervention and the need for ongoing research to improve outcomes in these patients. A multidisciplinary approach is crucial for optimal management.
DOI: 10.6084/m9.figshare.29235929.v1
title: Supplementary Material for: Remarkable Response to Cisplatin-Based Chemotherapy and Long-Term Remission in a Young Male with Widespread Extragonadal Choriocarcinoma: A Case Report and Literature Review

description: Introduction
Choriocarcinoma is a rare and aggressive germ cell tumor (GCT) that presents significant diagnostic challenges, particularly in males, where it is typically found in the gonads. Most patients present with advanced disease, often exhibiting symptoms related to metastatic spread, such as shortness of breath, cough, and hemoptysis. The rarity of extragonadal choriocarcinoma and its non-specific presentation make early diagnosis difficult, emphasizing the need for a multidisciplinary approach to treatment.
Case Presentation
A 31-year-old male presented with progressive shortness of breath, cough, and hemoptysis over a month. Initial imaging revealed multiple pulmonary nodules and a large necrotic retroperitoneal mass, along with liver metastases. The patient’s β-human chorionic gonadotropin (β-hCG) levels were markedly elevated, raising suspicion of choriocarcinoma, which was subsequently confirmed through biopsy. Given the rapid clinical deterioration, chemotherapy with Cisplatin and Etoposide was initiated. The patient responded well to treatment, with a significant reduction in tumor and metastasis size. Over 30 months of follow-up, the patient showed continued clinical improvement with no evidence of disease recurrence.
Conclusion
Extragonadal choriocarcinoma is a highly aggressive and rare malignancy that poses significant diagnostic and therapeutic challenges. This case underscores the importance of early intervention and the need for ongoing research to improve outcomes in these patients. A multidisciplinary approach is crucial for optimal management.
DOI: 10.15468/dl.eabxpn
title: Occurrence Download

description: A dataset containing 12 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Canistrum paulistanum (Leme) Wand. & S.E.Martins"
 ]
}

 The dataset includes 12 records from 8 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0020029-250525065834625/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.29235932
title: Supplementary Material for: Comparison of local recurrence outcomes between breast conservation therapy and mastectomy for the treatment of breast cancer among young women: A systematic review and meta-analysis

description: Background: Recent clinical trials comparing local recurrence rates in young breast cancer (BC) patients after breast-conserving therapy (BCT) versus mastectomy are limited. The local recurrence (LR) rate in young breast cancer patients is notably higher than in other age groups, whether the recurrence rates after the two surgical options are comparable remains unclear. This meta-analysis aims to assess the safety of BCT and mastectomy for young age BC patients by comparing LR rates between the two procedures.
Methods: We conducted a systematic search of four electronic databases (Medline, PubMed, Cochrane Library, and Web of Science) for relevant studies comparing LR rates in BC patients aged 40 years or younger who were treated with BCT or mastectomy. Studies that met the inclusion criteria were synthesized using a random-effects model, with a primary focus on LR rates. Sensitivity analyses and meta-regression were performed to evaluate bias and heterogeneity, ensuring a thorough assessment of the available evidence.
Results: Among the 2936 studies screened, 10 studies encompassing 9,215 patients were included, with 5236 undergoing BCT and 5803 undergoing mastectomy. The summary odds ratio (OR) indicated a significantly greater risk of LR for BCT compared to mastectomy among young BC patients (OR = 1.48; 95% CI: 1.12–1.96). In subgroup analysis, the BCT group exhibited a higher 5year LR rate (OR=1.67; 95% CI: 1.13–2.46) compared to the mastectomy group. This trend persisted across tumor stages, with the BCT group showing an increased LR risk in both the T1-2 (OR=1.84; 95% CI: 1.44–2.36) and T1-4 (OR = 1.74, 95% CI: 1.50–2.03) stages. Nodal status analysis indicated a higher LR risk for BCT in the N0-1 (OR = 2.549, 95% CI: 1.79–3.46) stages. Among very young women (aged ≤ 35), the difference in LR rates between BCT and mastectomy was even more pronounced (OR = 2.04, 95% CI: 1.47–2.82).
Conclusion: Our meta-analysis found that young BC patients undergoing BCT had a significantly higher risk of LR, with a 48% increased risk compared to those who underwent mastectomy (OR = 1.48; 95% CI: 1.12–1.96). This difference was even more pronounced in patients aged 35 years or younger. While the elevated LR risk with BCT in young patients is well-documented, individualized treatment planning should weigh this against potential survival advantages and quality-of-life preservation.